For instance, galunisertib, an inhibitor of TGFBR1, blocks the function TGF-β signalling and enhances the anti-tumour effects of CD133 and Her2 chimeric antigen receptor (CAR) T cells against both glioma and breast cancer [155]. This evidence concerns the gene TGFBR1 and neoplasm.